Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

被引：12

作者：

Zain, Jasmine ^{[1
]}

机构：

[1] NYU Langone Med Ctr, Div Hematol Malignancies & Med Oncol, New York, NY 10016 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 03期

关键词：

Histone deacetylase inhibitors; Lymphoma; Multiple myeloma; Epigenetic therapy; SUBEROYLANILIDE HYDROXAMIC ACID; PERIPHERAL T-CELL; PHASE-II TRIAL; VALPROIC ACID; GENE-EXPRESSION; DEPSIPEPTIDE FR901228; HODGKIN LYMPHOMA; HDAC INHIBITOR; EPIGENETIC THERAPIES; FK228; DEPSIPEPTIDE;

D O I：

10.1016/j.hoc.2012.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymphomas, mantle cell lymphomas, and Hodgkin disease. The bigger promise of these agents is in enhancing the activity of other targeted therapies. In addition, the effects of HDACI on the immune system and cytokines indicate that HDACI can be useful in the treatment of immune dysfunction underlying tumorigenesis, autoimmune disorders, and graft-versus-host disease. There is also an effort to determine whether class specificity of HDACI has a biologic significance.

引用

页码：671 / +

页数：35

共 180 条

[1] The proteasome: structure, function, and role in the cell [J].

Adams, J .

CANCER TREATMENT REVIEWS, 2003, 29 :3-9

[2]

Ali C M, 2011, Mymensingh Med J, V20, P497

[3] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[4]

Amengual J, 2011, BLOOD

[5]

[Anonymous], 2010, MED LETT DRUGS THER, V52, P42

[6]

[Anonymous], BLOOD

[7] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[8] Challenges of evaluating the cardiac effects of anticancer agents [J].

Bates, Susan E. ;

Rosing, Douglas R. ;

Fojo, Tito ;

Piekarz, Richard L. .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3871-3874

[9] Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma [J].

Bates, Susan E. ;

Zhan, Zhirong ;

Steadman, Kenneth ;

Obrzut, Tomasz ;

Luchenko, Victoria ;

Frye, Robin ;

Robey, Robert W. ;

Turner, Maria ;

Gardner, Erin R. ;

Figg, William D. ;

Steinberg, Seth M. ;

Ling, Alex ;

Fojo, Tito ;

To, Kin Wah ;

Piekarz, Richard L. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (02) :256-267

[10] Epigenetic Therapies Reach Main Street [J].

Bates, Susan E. .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :3917-3917

← 1 2 3 4 5 6 7 8 9 10 →